September 27, 2023 — On September 26, 2023, the Food and Drug Administration approved bosutinib (Bosulif, Pfizer) for pediatric patients 1 year of age and older with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) that is newly diagnosed…Original Article
FDA Approves Bosutinib for Pediatric Patients with Chronic Myelogenous Leukemia
